Abstract 4279
Background
Conventional chemotherapy agents such as doxorubicinare not curative and new therapies for metastatic sarcomas are urgently needed. Apatinib (YN968D1) as a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) has been widely used as monotherapy or combined treatments. We performed a retrospective study with stage IV sarcoma cohort to investigate the efficacy of Apatinib with or without chemotherapy.
Methods
The information of 74 sarcoma patients in stage IV treated in Tianjin Medical University Cancer Hospital was collected and approved by the Institutional Review Board. Of these patients, 15 patients underwent Apatinib + traditional chemotherapy (combined group), and 59 received Apatinib as monotherapy (control group).
Results
We recruited 74 patients in this trial from Sep. 2015 to Apr. 2019. In the combined group, 6 of 15 patients (40.0%) recorded as partial response (PR), 7 of 15 patients (46.7%) recorded as stable disease (SD) and 2 patients (13.3%) was progressive disease (PD). The control group showed that 9 patients experienced PR (15.3%), 25 patients (42.4%) was SD and 25 patients (42.4%) was PD. The ORR (40.00% versus 15.25%, P = 0.034) and the DCR (86.67% versus 57.63%, P = 0.037) in the combined group showed significant higher than that of the control group. The median PFS of the combined group and control groups was 7.6 months and 7.9 months (P = 0.410). The median OS of the combined group and control group was 12.9 months and 17.3 months, respectively (P = 0.826). The mPFS and mOS shown no significant difference might due to the shorter follow-up time and small case number. Common AEs in combined group included hypertension (n = 7, 46.67%), hand-foot syndrome (n = 7, 46.67%), proteinuria (n = 8, 53.33%), anorexia (n = 4, 26.67%), fatigue (n = 4, 26.67%), transaminase increased (n = 4, 26.67%), diarrhea (n = 7, 46.67%), and anemia (n = 8, 53.33%), which all happened more frequently than in control group. No grade 4 AEs occurred, but 3 patients (20%) suffered from grade 3 AEs, which were mainly hypertension, hand-foot syndrome and proteinuria.
Conclusions
Chemotherapy combined with apatinib significantly increases the response rate and shows manageable adverse events.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1735 - mTOR inhibition in the treatment of resistant breast cancer
Presenter: María Rodriguez
Session: Poster Display session 1
Resources:
Abstract
6068 - Study of Photodynamic therapy in vitro
Presenter: Irene Jiménez Munguía
Session: Poster Display session 1
Resources:
Abstract
3011 - The potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models
Presenter: Neil Conlon
Session: Poster Display session 1
Resources:
Abstract
2644 - Novel HDACi, MHY446, induces apoptosis via regulation of mitochondria-endoplasmic reticulum interaction in HCT116 human colorectal cancer cells
Presenter: Nam Deuk Kim
Session: Poster Display session 1
Resources:
Abstract
3085 - Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer
Presenter: Davide Ciardiello
Session: Poster Display session 1
Resources:
Abstract
1314 - PARP inhibition enhances cisplatin sensitivity in cervical cancer by modulating β-catenin signaling
Presenter: Minakshi Mann
Session: Poster Display session 1
Resources:
Abstract
2417 - Synergistic effect of DSF combined treatment with cisplatin in atypical teratoid/rhabdoid tumors (AT/RT)
Presenter: Seung Ah Choi
Session: Poster Display session 1
Resources:
Abstract
1149 - Reactive oxygen species induced by OSU-A9 inhibit the growth of duodenal cancer and gastric cancer cells through dephosphorylating intranuclear pyruvate kinase muscle isozyme M2
Presenter: Li-Yuan Bai
Session: Poster Display session 1
Resources:
Abstract
1862 - New therapy for intrahepatic cholangiocarcinoma targeted to cancer associated fibroblasts
Presenter: Takahiro Yamanaka
Session: Poster Display session 1
Resources:
Abstract
782 - Macrophage-cancer cell fusion is mediated by Phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation
Presenter: Ivan Shabo
Session: Poster Display session 1
Resources:
Abstract